What is Royalty Pharma's total funding, tev-408 — total commitments?

Royalty Pharma (RPRX) reported total funding, tev-408 — total commitments of $75.00M in Q1 2026.

What does total funding, tev-408 — total commitments mean?

The total amount of capital the company has committed to invest in a specific biopharmaceutical program.

Products & Services · Total Commitments

Total Funding, TEV-408 — Total Commitments

Analysis

StatementSegment

CategoryCapital Allocation

SignalContext dependent

VolatilityStable

First reportedQ1 2026

Last reportedQ1 2026

Rolls up toTotal Commitments

How to read this metric

An increase indicates expanded investment in a specific asset class or therapeutic area, while a decrease suggests a reduction in long-term capital allocation to that segment.

Detailed definition

This metric represents the aggregate capital commitment allocated to a specific biopharmaceutical development program or...

Peer comparison

Comparable to total committed capital or project-specific investment ceilings reported by private equity firms or specialized biopharma investment funds.

Metric ID: rprx_segment_total_funding_tev_408_total_commitments

Historical Data

1 periods

	Q1 '26
Value	$75.00M

Similar Metrics at Other Companies

United TherapeuticsUTHR View metric

BiogenBIIB View metric

Prudential FinancialPRU View metric

Natera, Inc.NTRA View metric

Frequently Asked Questions

What is Royalty Pharma's total funding, tev-408 — total commitments?: Royalty Pharma (RPRX) reported total funding, tev-408 — total commitments of $75.00M in Q1 2026.
What does total funding, tev-408 — total commitments mean?: The total amount of capital the company has committed to invest in a specific biopharmaceutical program.